On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...